Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: Comparison of 800/100 mg and 400/100 mg twice daily

HIV Medicine

Volumn 6, Issue 1, 2005, Pages 1-6

  Konopnicki, D ^a   De Wit, S ^a   Poll, B ^a   Crommentuyn, K ^b   Huitema, A ^b   Clumeck, Nathan ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Convenience; Dosage; Efficacy; Indinavir; Tolerance

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; RITONAVIR; TREATMENT OUTCOME; TRIGLYCERIDES; VIRAL LOAD;

EID: 13944254107     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00255.x     Document Type: Article

References (22)

1. Haubrich RH, Little SJ, Currier JS et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 13: 1099-1107.
2. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19 708-712.
3. Burger DM, Hoetelmans RM, Hugen PW et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998; 3: 215-220.
4. Hsu A, Granneman GR, Cao G et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 2784-2791.
5. Van Heeswijk RP, Veldkamp AI, Hoetelmans RM et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13: F95-F99.
6. Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR, Deutsch PJ. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother 2001; 45: 2710-2715.
7. Voigt E, Wickesberg A, Wasmuth JC et al. First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Med 2002; 3: 277-282.
8. Young B, Fischl MA, Wilson HM et al. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. J Acquir Immune Defic Syndr 2002; 31: 478-482.
9. Arnaiz JA, Mallolas J, Podzamczer D et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003; 17: 831-840.
10. Lamotte C, Peytavin G, Perre P et al. Increasing adverse events with indinavir dosages and plasma concentrations in four different ritonavir- indinavir containing regimen in HIV-infected patients. VIII Conference on Retroviruses and Opportunistic Infections Chicago, IL, February 2001 [Abstract 738].
11. Dieleman JP, Gyssens IC, Van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HTV-infected patients. AIDS 1999; 13: 473-478.
12. Durant J, Clevenbergh P, Garraffo R et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14: 1333-1339.
13. Konopnicki D, De Wit S, Protto J, Sommereijns B, Clumeck N. Efficacy and safety of indinavir 800 ing bid versus 400 mg bid combined with ritonavir 100 mg bid in naive patients. XIV International AIDS Conference. Barcelona, July 2002 [Abstract TuPeB4456].
14. Crommentuyn KML, Rosing H, Nan-Offeringa LGAH, Hillebrand MJX, Huitema ADR, Beijnen JH. Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 2003; 38: 157-166.
15. Ghosn J, Lamotte C, Ait-Mohand H et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17: 209-214.
16. Justesen US, Levring AM, Thomsen A, Lindberg JA, Pedersen C, Tauris P. Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up. HIV Med 2003; 4: 250-254.
17. Walmsley S, Bernstein B, King M et al.. M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046.
18. Langmann P, Zilly M, Weissbrich B, Desch S, Vath T, Klinker H. Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART. Infection 2002; 30: 13-16.
19. Alexander CS, Asselin JJ, Ting LS et al. Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis 2003; 188: 541-548.
20. Garcia-Silva J, Almagro M,, Pena-Penabad C, Fonseca E. Indinavir-induced retinoid-like effects: incidence, clinical features and management. Drug Safety 2002; 25: 993-1003.
21. Solas C, Basso S, Poizot-Martin I et al. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr 2002; 29: 374-377.
22. Meraviglia P, Angeli E, Del Sorbo F et al. Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. AIDS 2002; 16: 2089-2093.